State laws in Florida allow card-holding seniors to use cannabis, but federally-subsidized senior homes must go against status-quo to allow this. The benefits are not being denied, but if they want to participate in Medicare then cannabis use comes with great risk. http://bit.ly/2LmKJZg
Some people are concerned that Cannabinoid Hyperemesis Syndrome (CHS,) a rare condition involving cyclical vomiting, may be caused by neem oil or pesticides. However, symptoms are more consistent with an overload of CB1 receptors, circumstances that occur primarily with habitual, large-volume consumers. Here, an interesting review of the ongoing public conversation: http://bit.ly/2LepwAV
To explore related information, click the keywords below:
Cannabis-based treatments may reduce seizures among children with drug-resistant epilepsy, but are these treatments cost-effective?
Economic evaluations of cannabis treatments are needed, and they should address issues including weight-gain over time, switching or discontinuation of treatments, the effectiveness of interventions, and long-term success, beyond the duration of available clinical studies.
This paper is also stored here: http://bit.ly/2INWAOJ inside the CED Foundation Archive
To explore related information, click the keywords below:
Kudos to Kyle Jaeger for a helpful summary of last week’s US House’s vote on an amendment to block the Department of Justice from interfering in states’ legal cannabis programs. His work outlines which representatives stand where, with regard to #cannabis. Interesting to see, and how times change! http://bit.ly/2LgKO0P
To explore related information, click the keywords below:
In what may be considered preemptive action, Oregon legislature passed Senate Bill 582, allowing the governor to enter agreements with other states for cannabis import and export. This hinges on the federal government, but if so, Oregon aims to be a national supplier of cannabis. https://lat.ms/2LezJ00
Preliminary testing shows positive results towards using CBD as an antibiotic topically, but also potentially to deal with systematic infections, such as pneumonia, using oral dosing. One of the present concerns is the struggle of getting permits to handle these cannabinoids to do further testing.
While these specific findings have not yet been published in a peer-review journal, this is far from the first time we have seen antimicrobial activity associated with plants or with cannabis. Evolutionarily, this trait is believed to be adaptive for the plant, and within cannabinoid, terpenoid, and flavonoid compounds, this activity has been demonstrated reproducibly, both in the lab and in clinic.
http://bit.ly/2LbTwxm
To explore related information, check the CED Foundation MMJ archive to search, or click the keywords below:
Human study finds that, when taken with opioids, dronabinol (THC) may increase impairment and decrease, or not affect, pain relief. Researchers conclude that THC might NOT protect the body from the adverse effects of opioids. However, the study examined only 10 participants, and such a small sample size should give pause to the validity and applicability of the findings.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2IHJuSO inside the CED Foundation Archive
To explore related information, click the keywords below:
“Cannabis hyperemesis syndrome: still under-recognized after all these years“
After two years of chronic vomiting and pain and dozens of trips to emergency rooms a 23-year-old woman was found to have cannabis hyperemesis syndrome (CHS). Physicians are still unable to recognize the early symptoms of CHS as cannabis use is still in a legal gray area in much of the country. A lack of research, recognition, and trust often prevents a quick diagnosis when an illness is related to cannabis, leading to multiple referrals and invasive tests.
CHS was first described 15 years ago yet it is not frequently recognized in patients. The case study featured in this blog post highlights patients and physicians’ outcry for tolerance and support so that cannabis-related illnesses can be efficiently and effectively engaged.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2IxMxNx inside the CED Foundation Archive
To explore related information, click the keywords below:
The cannabis conundrum: thinking outside the THC box
A commentary on cannabis-based medicine points out some of the limitations in previous research, suggests implications of those limitations, and recommendations for future research. The legal status of cannabis, at the national level, hinders researchers’ ability to discover more beneficial or harmful effects. Furthermore, the variability of cannabinoids present within different strains of cannabis limits real-world applications of cannabis-based medicine. Currently, there is no scientific foundation for policies or regulatory practices, leaving room for improvement as states continue to legalize the use of medical cannabis.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/31CmXOU inside the CED Foundation Archive
To explore related information, click the keywords below:
Exciting note to Massachusetts medical cannabis patients: Beginning July 1, medical patients will have the opportunity for an “Initial Access Certification” once they have seen their certifying physician.
This access is good for 14 days, so patients will no longer have to wait for the state approval process before having access to medication.
More info: http://bit.ly/2LmFY1Q
View the full documentation (yellow link) or download:
